Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial

Lancet

Volumn 369, Issue 9556, 2007, Pages 123-131

  Conter, Valentino ^a   Valsecchi, Maria Grazia ^a   Silvestri, Daniela ^a   Campbell, Myriam ^b   Dibar, Eduardo ^c   Magyarosy, Edina ^d   Gadner, Helmut ^e   Stary, Jan ^f   Benoit, Yves ^g   Zimmermann, Martin ^h   Reiter, Alfred ⁱ   Riehm, Hansjörg ^h   Masera, Giuseppe ^a   Schrappe, Martin ^j  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b HOSPITAL ROBERTO DEL RÍO   (Chile)

^c HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^f UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY HOSPITAL GIESSEN   (Germany)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; FEMALE; FOLLOW UP; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SURVIVAL TIME;

EID: 33846100277     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60073-7     Document Type: Article

References (28)

1. Riehm H., Gadner H., Henze G., et al. Results and significance of six randomized trials in four consecutive ALL-BFM trials. Haematol Blood Transfus 33 (1990) 439-450
2. Conter V., Aricò M., Valsecchi M., et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Acute Lymphoblastic Leukemia Studies, 1982-1995. Leukemia 14 (2000) 2196-2204
3. Schrappe M., Reiter A., Zimmermann M., et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 14 (2000) 2205-2222
4. Gaynon P., Trigg M., Heerema N., et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 14 (2000) 2223-2233
5. Pui C., Boyett J., Rivera G., et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 14 (2000) 2286-2294
6. Reiter A., Schrappe M., Ludwig W., et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood 84 (1994) 3122-3133
7. Conter V., Schrappe M., Aricò M., et al. Role of cranial radiotherapy for childhood T-ALL acute lymphoblastic leukaemia with high WBC count and good response to prednisone. J Clin Oncol 15 (1997) 2786-2791
8. Carroll W., Bhojwani D., Min D., et al. Pediatric acute lymphoblastic leukemia. Haematology. Am Soc Hematol Educ Program (2003) 102-131
9. Sallan S., Gelber R., Kimball V., Donnelly M., and Cohen H. More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus 33 (1990) 459-466
10. Bleyer W., Sather H., Nickerson H., et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Childrens Cancer Study Group. J Clin Oncol 9 (1991) 1012-1021
11. Holland J., and Glidewell O. Chemotherapy of acute lymphocytic leukaemia of childhood. Cancer 30 (1972) 1480-1487
12. Pinkel D., Hernandez K., Borrella L., et al. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 27 (1971) 247-256
13. Tubergen D., Gilchrist G., O'Brien R., et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol 11 (1993) 527-537
14. Chessells J., Bailey C., and Richards S. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Lancet 345 (1995) 143-148
15. Henze G., Fengler R., Reiter A., Ritter J., and Riehm H. Impact of early intensive reinduction therapy on event-free survival in children with low-risk acute lymphoblastic leukemia. Haematol Blood Transfus 33 (1990) 483-488
16. Clavell L., Gelber R., Cohen H., et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315 (1986) 657-663
17. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12000 randomised children. Lancet 347 (1996) 1783-1788
18. Kaspers G., Veerman A., Popp-Snijders C., et al. Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 27 (1996) 114-121
19. Klumper E., Pieters R., Veerman A., et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood 86 (1995) 3861-3868
20. Jones B., Freeman A., Shuster J., et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19 (1991) 269-275
21. Bostrom B., Sensel M., Sather H., et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 101 (2003) 3809-3817
22. Veerman A., Hahlen K., Kamps W., et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14 (1996) 911-918
23. Masera G., Gadner H., Kamps W., et al. The treatment of childhood acute lymphoblastic leukemia. The International BFM Study Group experience. Int J Pediatr Hematol Oncol 5 (1998) 141-144
24. Valsecchi M., and Masera G. A new challenge in clinical research in childhood ALL: the prospective meta-analysis strategy for intergroup collaboration. Ann Oncol 7 (1996) 1005-1008
25. Bennett J., Catovsky D., Daniel M., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33 (1976) 451-458
26. van der Does-van den Berg A., Bartram C., Basso G., et al. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM Family" Cooperative Group. Med Pediatr Oncol 20 (1992) 497-505
27. Cox D. Regression models and life-tables. J R Stat Soc B 34 (1972) 187-220
28. Arico M., Baruchel A., Bertrand Y., et al. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, Jan 29-30, 2005. Leukemia 19 (2005) 1145-1152